KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.

Andrew Ustianowski, Myron J Levin, Stephane De Wit, Odile Launay, Bernard Veekmans, Tommy Rampling, James G Sullivan, Mark Vishnepolsky, Priyantha Wijewardane, Yousef Fawadleh, Huixia Zhang, Meng Li, Dilki Wickramarachchi, Audrey Sharbaugh, Rohini Beavon, Jesse Thissen, Lauren Hirao, Vitalina Dzutseva, Seth Seegobin, Katie Streicher, Alexandre Kiazand, Mark T Esser, Lee-Jah Chang, John L Perez, Taylor S Cohen

Clin Drug Investig 46(2) 207-219

PMID41545648
PMCIDPMC12872691
DOI10.1007/s40261-025-01515-x
发表日期2026-01-16
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。
摘要

摘要

BACKGROUND AND OBJECTIVES: The PROVENT study demonstrated the efficacy and safety of a single 300-mg dose of AZD7442 (tixagevimab/cilgavimab) for pre-exposure prophylaxis of COVID-19 in at-risk individuals. Here we report an analysis of repeat dosing of intramuscular AZD7442 300 and 600 mg from the PROVENT sub-study. METHODS: The sub-study enrolled eligible participants from the parent study, creating four sub-study groups. Group 1 received AZD7442 300 mg in PROVENT followed by one 300-mg dose in the sub-study (10-14 months apart). Group 2 received placebo in PROVENT followed by two AZD7442 300-mg doses 6 months apart in the sub-study. Group 3a received AZD7442 300 mg in PROVENT followed by one 300-mg dose and two 600-mg doses 6 months apart in the sub-study. Group 3b received placebo in PROVENT followed by one 300-mg dose and two 600-mg doses 6 months apart in the sub-study. The primary endpoint was safety. Secondary endpoints included pharmacokinetics and anti-drug antibody (ADA) responses. RESULTS: Adverse events (AEs) and serious AEs (SAEs) were reported in 75.7-81.5% and 13.2-16.8% of participants, respectively. AZD7442-related AEs, SAEs, and AEs of special interest occurred in 1.4-5.3%, 0-0.2%, and 0-5.3% of participants, respectively, and 3.9-6.7% experienced ≥ 1 cardiac and/or thromboembolic SAE. AZD7442 serum concentrations were dose-dependent with minimal accumulation following redosing, and 4.1-10.7% had treatment-emergent ADAs to AZD7442. CONCLUSIONS: AZD7442 safety, pharmacokinetic, and ADA response profiles were similar regardless of repeat dosing schedule, and consistent with single-dose study data. These results may support future use of long-acting antibodies. GOV REGISTRATION: NCT04625725.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 PROVENT sub-study design. AZD7442 tixagevimab/cilgavimab
非 KM Figure
Fig. 2Fig. 2 Participant disposition. ADA anti-drug antibody, AZD7442 tixagevimab/cilgavimab, nAb neutralizing antibody, PK pharmacokinetic
非 KM Figure
Fig. 3Fig. 3 Geometric mean (± gSD) serum concentrations of AZD7442, (A) linear and (B) logarithmic scales (PK analysis set). At baseline, the number of PK-evaluable participants was 266 in Group 1, 81 in Group 2, 74 in Group 3a, and 65 in Group 3b. Baseline was defined as the last non-missing measurement taken before the first dose of AZD7442. For participants in Groups 1 and 3a, the first dose of AZD7442 occurred in the PROVENT parent study. For Groups 2 and 3b, the first dose of AZD7442 occurred in the PROVENT sub-study. Serum concentrations below the LLOQ (0.3 µg/mL) at baseline were set to half the LLOQ. Figure adapted from Ustianowski et al [11]. AZD7442 tixagevimab/cilgavimab, gSD geometric standard deviation, LLOQ lower limit of quantification, PK pharmacokinetic
非 KM Figure
Fig. 4Fig. 4 Proportions of participants with ADA responses to AZD7442 (AZD7442 ADA evaluable analysis set). The AZD7442 ADA evaluable set consisted of all participants in the safety analysis set who were tixagevimab ADA evaluable or cilgavimab ADA evaluable. ADA anti-drug antibody, AZD7442 tixagevimab/cilgavimab, TE-ADA treatment-emergent anti-drug antibody. a ADA positive at any visit including baseline. b ADA negative at baseline and ADA positive at ≥ 1 post‑baseline assessments with ADA titer ≥ 2 times the assay limit (≥ 160 for tixagevimab; ≥ 80 for cilgavimab), or ADA positive at baseline with a ≥ 4-fold increase in ADA titer during the study. c Either tixagevimab or cilgavimab is persistently TE-ADA positive. d TE-ADA positive but not fulfilling the conditions of persistently positive
非 KM Figure